【摘要】 目的　观察血管紧张素转换酶抑制剂培哚普利对慢性心力衰竭 (CHF)的远期预后。方法　选择CHF患者 72例 ,随机分为对照组 (2 9例 )和治疗组 (43例 )。对照组采用综合疗法。治疗组在上述基础上加用培哚普利 (2～ 4mg/d)。在治疗前和观察期满 4年时分别对心功能NYHAⅡ～Ⅲ级患者作踏车负荷试验 ,记录患者所能耐受的最大运动功率和运动持续时间。结果　 4年期间 ,对照组和治疗组因心力衰竭加重再住院率分别为 82 76 %和 2 5 58% (P <0 0 0 5) ,病死率分别为 31 0 3 %和 9 30 % (P <0 0 2 5) ;与治疗前相比 ,治疗组心功能 (NYHA分级 )、最大运动功率和运动持续时间均明显改善 (P <0 0 0 1 ) ,而对照组各项指标无明显改善。结论　培哚普利可显著改善CHF患者的远期预后。更多还原

【Abstract】 Objective To investigate the long term effect of perindopril on the patients with chronic heart failure (CHF) Methods Seventy two CHF patients were divided into the treatment group (43 cases) and the control group (29cases) randomly The general therapy was given to the control group Besides this therapy, perindopril (2 mg 4 mg) was added to the treatment group The pedal stress test performed in the CHF patients with NYHA class II III prior to and at the end of 4 year treatment The maximum motion quantity (Mqmax) and the motion continuance time (MCT) were recorded Results The rehospitalization rate was 82 76% in the control group and 25 58% in the treatment group ( P <0 005) The mortality rate was 31 03% in the control group and 9 30% in the treatment group ( P <0 025) within 4 years After 4 years, the heart function (NYHA),Mqmax and MCT improved obviously in the treatment group ( P <0 001,respectively) but did not change significantly in the control group Conclusion The long term prognosis could be improved by perindopril in the CHF patients更多还原